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Abstract 
Chronic abuse of alcohol leads to various histological 
abnormalities in the liver. These are conditions collec-
tively known as alcoholic liver disease (ALD). Currently, 
ALD is considered to be one of the major causes of 
death worldwide. An impaired intestinal barrier with 
related endotoxemia is among the various pathogenetic 
factors. This is mainly characterized by circulating lev-
els of lipopolysaccharide (LPS), considered critical for 
the onset of intra-hepatic inflammation. This in turn 
promotes hepatocellular damage and fibrosis in ALD. 
Elevated levels of LPS exert their effects by binding to 
Toll-like receptors (TLRs) which are expressed by all 
liver-resident cells. The activation of TLR signaling trig-
gers an overproduction and release of some cytokines, 
which promote an autocatalytic cascade of other pro-
inflammatory signals. In this review, we provide an 
overview of the mechanisms that sustain LPS-mediated 
activation of TLR signaling, reporting current experi-
mental and clinical evidence of its role during inflam-
mation in ALD.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Alcoholic liver disease (ALD) pathogenesis is 
quite complex and requires the activation/inhibition of 
several molecular pathways. The inflammatory storm 
caused by alcohol abuse on the gut-liver axis and con-
sequent activation of Toll-like receptor (TLR) signaling 
is topical for researchers and physicians, both for un-
derstanding ALD pathophysiology and for translating 
novel clues into clinical practice. Here, we focus on the 
current evidence of TLR involvement in inflammation 
during ALD in experimental models and humans, offer-
ing readers with no first-hand knowledge of this topic a 
valuable tool to start novel studies.
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INTRODUCTION
Toll-like receptors (TLRs) belong to the family of  pat-
tern recognition receptors and are crucial sensors of  the 
innate immune system committed to the recognition of  
both pathogen and damage-associated molecular patterns 
(PAMPs and DAMPs, respectively)[1-4]. TLRs are key mol-
ecules of  the innate immune system which play a major 
role in the control of  the inflammation process, promot-
ing the production of  several circulating inflammatory 
molecules, including cytokines, chemokines and other 
molecules that may participate in tissue repair or exacer-
bate tissue damage in several diseases[5]. It is noteworthy 
that TLRs have also been implicated in both liver physiol-
ogy and in the pathophysiology of  several liver diseases 
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as they are diffusely expressed in all types of  liver cells[6-8]. 
The integrity of  the intestinal barrier and appropriate 
gut permeability are crucial for maintaining the equilib-
rium of  commensal and pathogenic microorganisms and 
for avoiding their translocation from the gut. Normally, 
only bacterial traces can pass the intestinal mucosa and 
reach the liver through the portal circulation where their 
clearance is accomplished. A large amount of  the lit-
erature in animal models and humans has reported that 
excessive alcohol consumption increases intestinal per-
meability, disrupting the intestinal barrier and leading to a 
strong increase of  portal and systemic levels of  the most 
studied PAMP, lipopolysaccharide (LPS)[9-12]. However, 
only recently through novel metagenomic and metapro-
teomic approaches, the ability of  acute and chronic in-
gestion of  alcohol to alter gut microbiota composition by 
increased bacterial overgrowth and contributing to liver 
damage and inflammation has emerged[13-15]. 
Over the past decade, despite numerous prevention 
campaigns, alcohol consumption is still at alarming levels, 
particularly in industrialized countries[16]. Therefore, alco-
hol abuse is currently considered to be one of  the major 
causes of  chronic liver disease in Western countries, 
particularly in Europe, southern Europe and the United 
Kingdom[17]. Prevalently, heavy drinkers are susceptible to 
develop alcoholic liver disease (ALD) which may be char-
acterized by different histological abnormalities, including 
steatosis, steatohepatitis and fibrosis, and evolving into 
more severe forms of  liver injury, such as cirrhosis and 
hepatocellular carcinoma (HCC)[17,18].
During the last decade, the importance of  research and 
clinical studies of  the underlying molecular mechanisms 
that link TLRs and ALD have received increasing interest, 
particularly because of  their therapeutic inference.
In the present review, we focus on the implication of  
TLRs and their role in inflammation in ALD pathogen-
esis and we provide an overview of  their possible clinical 
impact in prevention and therapy.
TLR-MEDIATED SIGNALING
TLRs are regulators of  innate immune response and sen-
sors of  both the pathogen signature bacteria, fungi and 
virus PAMPs and the endogenous components, DAMPs. 
They are highly conserved type I transmembrane pro-
teins which comprise an extracellular leucine-rich ligand 
binding domain and an intracellular domain, Toll/in-
terleukin (IL)-1 receptor (TIR) domain, responsible for 
their intracellular signal transduction[19]. TLRs have been 
classified based on their ligand specificity and selectivity, 
accounting for more than 13 members in mammals, of  
which 11 are expressed in humans. However, each human 
TLR exhibits differential activities, depending on its tis-
sue expression and ligand specificity[20].
In the liver, TLRs are expressed in Kupffer cells (KCs), 
hepatocytes and hepatic stellate cells (HSCs) and they 
have been extensively studied in various chronic liver 
diseases[21]. In more detail, TLR2 and TLR4 expression is 
shared by hepatocytes, KCs, HSCs and biliary epithelial 
cells, while TLR4 is also expressed by sinusoidal endo-
thelial cells. Moreover, KCs also express both TLR3 as 
biliary epithelial cells and TLR9, similar to HSCs and si-
nusoidal endothelial cells[22].
LPS, a component of  Gram-negative bacteria walls, 
composed of  a carbohydrate (O-antigen), an oligosaccha-
ride region and a lipid part (called Lipid A), is the ligand 
of  TLR4. TLR4 cannot bind directly as the LPS molecule 
requires a complex assembly composed by the CD14 co-
receptor which facilitates the transfer of  LPS to TLR4 
complex and MD-2, an adapter molecule that modulates 
the LPS recognition. Another cofactor is LPS-binding 
protein (LBP) that shuttles LPS to the CD14 molecule. 
The association of  these auxiliary molecules triggers the 
signal, resulting in the homodimerization of  TLR4 mol-
ecules and consequent signaling[23,24].
Once TLRs have bound their specific ligands on the 
cell membrane, they transduce the downstream signal by 
means of  the myeloid differentiation factor 88 (MyD88), 
a common molecule adaptor for all TLRs except TLR3[25]. 
Actually, the TLR downstream signaling can be distin-
guished as MyD88-dependent or MyD88-independent 
pathways with the alternative adapter molecule as TIR-
domain-containing adapter-inducing interferon-β (TRIF). 
As a final effect, MyD88-dependent cascade leads to the 
activation of  nuclear factor-κB and activating protein-1 
(AP-1) by means of  IκB kinase (IKK) complex and mito-
gen-activated protein kinases (MAPKs) respectively. NF-
κB and AP-1, in turn, conduct the production of  specific 
pro-inflammatory cytokines, such as tumor necrosis fac-
tor (TNF)-α, IL-6 and IL-1β[25]. In the liver, the MyD88 
pathway also promotes the activation of  the LPS-induced 
TNF-α factor (LITAF), another transcription factor that 
regulates the transcription of  pro-inflammatory cyto-
kines[26]. Conversely, MyD88-independent cascade pre-
dominantly induces the expression of  Type I interferons 
by the activation of  IRF-3 through the critical regulators 
TANK-binding kinase 1 (TBK1) and IKKs[27]. 
KC-dependent production and release of  pro-
inflammatory cytokines, such as TNF-α and IL-1β, will 
further increase production and release of  other pro-
inflammatory cytokines (i.e., IL-6 and IL-8) and chemoat-
tractant factors in a vicious cycle, leading to the activation 
of  other immune cells, including neutrophils, monocytes 
and lymphocytes. These immune cells in turn also re-
spond to TLR activation in KCs, generating reactive oxy-
gen species (ROS), increasing phagocytosis and secreting 
anti-microbial peptides and a cascade of  additional pro-
inflammatory molecules[28].
In Figure 1 we have schematized the LPS-mediated 
TLR4 signaling pathways leading to intra-hepatic inflam-
mation.
TLR ROLES IN ALD PATHOGENESIS
ALD pathogenesis
ALD is considered to be one of  the major causes of  
death worldwide, accounting for half  of  alcohol-related 
fatalities[17]. Excessive alcohol consumption may lead to 
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several liver tissue abnormalities. Therefore, histologi-
cal features in ALD include steatosis, steatohepatitis and 
fibrosis, which may progress to cirrhosis and ultimately 
to HCC[29]. Although research interests in ALD patho-
genetic mechanisms have increased during the last de-
cades, some relevant pathways have only recently been 
characterized[30]. Studies on the direct effect of  alcohol 
on intestinal permeability have shown that acetaldehyde, 
the most toxic metabolite of  ethanol metabolism, has 
a major role in the increment of  tight junction tyrosine 
phosphorylation, conducting altered localization of  both 
tight junction (occludin and ZO1) and adherens junction 
(E-cadherin and β-catenin) molecules[31,32].
Intra-hepatic lipid accumulation and steatosis in 
people who drink a toxic alcohol amount (40-80 g/d for 
men and 20-40 g/d for women for 10 years) is character-
ized by the impairment of  the major pathways involved 
in alcohol metabolism, including its conversion to ac-
etate by the activity of  specific dehydrogenases which 
completes the conversion to acetate and mitochondrial 
fatty acid oxidation[33]. Furthermore, development of  the 
progressive severe forms of  ALD-related liver damage, 
such as steatohepatitis and fibrosis, results from a com-
plex interplay between the oxidative stress due to release 
of  ROS and the activation of  several components of  the 
innate immune system due to endotoxins such as LPS[34]. 
Besides, several studies suggested that LPS increases cy-
tokine levels by NAPDH oxidase and ROS production 
in macrophages via the NF-κB pathway[35]. Although the 
complex upstream and downstream events and molecules 
that may explain the LPS-mediated mechanisms in ALD 
have been a subject of  deep investigation for decades, 
they are only recently becoming clear[21]. Alcohol-induced 
LPS accumulation and consequent endotoxemia may oc-
cur by the alteration of  gut-microbiome composition, 
which leads to endotoxin over-production and conse-
quent disruption of  intestinal barrier integrity. Therefore, 
the increased alcohol-mediated endotoxemia may reduce 
the detoxifying ability of  KCs and the activation of  the 
TLR4-mediated inflammatory response that promotes 
hepatocellular injury. Experimental and clinical evidence 
of  this complex network of  TLR4-associated upstream 
and downstream factors involved in ALD-associated in-
flammation are reported in the next paragraphs.
Evidence from animal models
The involvement of  gut-derived microbial products, such 
as LPS, which can pass the systemic and portal circulation 
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Figure 1  Schematic representation of lipopolysaccharide-mediated Toll-like receptor 4 signaling pathways. The disruption of intestinal integrity (i.e. caused by 
alcohol) results in migration of gut-derived microbial products, particularly LPS, through the portal circulation reaching the liver. LPS can prime KC-dependent produc-
tion and release of pro-inflammatory cytokines (as TNF-α and IL-1β), which in turn, lead to release of other pro-inflammatory cytokines and chemokines recruiting 
and activating immune cells, affecting HSC and hepatocyte homeostasis. In the figure, the LPS-TLR4 interaction and consequent initiation of downstream signaling 
cascade distinguishing both the MyD88-dependent and independent pathways in KCs and their interplay with other cells involved in liver inflammation and damage 
is summarized. LPS: Lipopolysaccharide; LBP: LPS-binding protein; KC: Kupffer cell; TNF: Tumor necrosis factor; IL: Interleukin; HSC: Hepatic stellate cell; TLR: 
Toll-like receptor; TIR: Toll/interleukin-1 receptor; TRIF: TIR-domain-containing adapter-inducing interferon-β; NF-κB: Nuclear factor-κB; IKK: IKB kinase; MAPKs: 
Mitogen-activated protein kinases; LITAF: LPS-induced TNF-α factor; IFN: Interferon; ROS: Reactive oxygen species.
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pate with a mechanism similar to that of  non-alcoholic 
fatty liver disease in the promotion of  ALD[7]. In fact, 
Wang et al[49] found that HMGB1 serum levels increased 
in chronic alcohol feeding of  mice and its balance with 
milk fat globule-EGF factor 8 may control macrophage 
efferocytosis.
Interestingly, a recent study in TLR4 deficient mice 
transplanted with bone marrow (BM)-derived cells (KCs) 
or non-BM-derived cells (HSCs included) demonstrated 
that in both liver cell lineages, TLR4 is essential for the 
progression of  alcohol-induced liver steatosis, inflam-
mation, injury and fibrosis[50]. Besides, ROS production 
has been implicated in the alcohol-induced sensitization 
to LPS. In more detail, it has been shown that the direct 
interaction between TLR4 and nicotinamide adenine di-
nucleotide phosphate (NADPH) oxidase isozyme (Nox)-4 
leads to NF-κB activation and LPS-mediated ROS gen-
eration in vitro[51]. In a chronic alcohol-fed rat model, the 
inhibition of  NADPH oxidase through diphenylenei-
odonium (DPI) diminished the LPS-induced ERK1/2 
phosphorylation and both ROS and TNF-α levels in 
KCs[52]. Furthermore, in C57Bl6/J mice fed a modified 
Lieber-De Carli diet, DPI protected from steatosis and 
liver inflammation induced by the usage of  diverse bacte-
rial components specific for different TLRs[48]. Previous 
evidence also showed that mice p47 phox -/-, depleted 
of  the main cytosolic part of  NADPH oxidase, were pre-
served from alcohol-induced liver injury, corroborating 
the crucial role of  oxidative stress in TLR signaling along 
the ALD condition[53]. 
By the way, TLR4 is an important player in the de-
velopment of  fatty liver, although how it can influence 
lipid metabolism has not been completely clarified. Ex-
perimental studies on TLR4 mutant animal models have 
documented that TLR4 is involved in lipid accumulation 
and lipid peroxidation imbalance[40,54].
It is established that KC activation due to alcohol 
intake can lead to an increment in the production of  pros-
taglandin (PG) E(2) which, interacting with prostanoid 
receptors and augmenting cAMP, can build up triglyceride 
in the liver. Furthermore, hepatic fat accumulation can be 
induced by the augmentation of  the NADH/NAD(+) 
ratio, the sterol regulatory element-binding protein-1 
(SREBP-1) activity and the decrease of  peroxisome prolif-
erator-activated receptor-alpha (PPAR-alpha) activity[55,56]. 
Also, microRNAs (miRNAs) have been implicated in 
the inflammation process in ALD and its complications. 
MiRNAs are conserved single-strand small noncoding 
RNAs which have a post-transcriptional gene-expression 
regulation function. They act on the 3’-untranslated 
mRNA target with whom miRNAs pair with different 
specificity. This match influences RNA stability and deg-
radation or the translation and finally leads to protein 
repression[57]. Specifically, miR-155 is a ruler of  inflamma-
tion and TLR signaling. It regulates TNF-α mRNA sta-
bility, as demonstrated in in vitro experiments performed 
on alcohol-treated macrophages[58]. Such evidence has 
been confirmed in a mouse model of  ALD in which iso-
due to the disruption of  the intestinal barrier caused by 
ethanol was suggested several years ago[36]. Furthermore, 
Keshavarzian et al[37] demonstrated that intestinal barrier 
dysfunction and endotoxemia are early events preceding 
ethanol-dependent hepatic injury in rats. Particularly, se-
rum LPS has been found to be increased in animal mod-
els resembling human ALD[38].
The relevance of  TLR4-dependent KC activation 
followed by the initiation of  the inflammatory cascade 
in the pathogenesis of  alcohol-induced liver damage has 
been also proved in models of  ALD[39,40]. Furthermore, 
studies performed on mice that have a functional muta-
tion in the TLR4 gene showed an impaired response to 
bacterial endotoxins[40]. Moreover, LBP knockout mice 
were significantly reduced in the pathological parameters 
characterizing ethanol-fed mice, such as endotoxin levels, 
steatosis, inflammation and liver injury[41]. Further, CD14 
knockout mice were protected from alcohol-caused se-
vere liver injury and from ethanol-induced NF-κB, trans-
forming growth factor (TGF)-β and TNF-α increase[42]. 
As previously described, TLR4 signaling encompasses 
two distinct cascades: the MyD88-dependent and the 
TRIF-dependent (MyD88-independent). 
These downstream pathways have been widely stud-
ied in animal models in order to clarify their respective in-
volvement in ALD pathogenesis. Experimental evidence 
established that in ALD, the TLR4 down-stream signal-
ing is principally regulated by the MyD88-independent 
cascade. In fact, while TLR4-knockout (KO) mice were 
protected from alcohol-induced liver damage, ROS pro-
duction and inflammation, MyD88-KO mice were not, 
both being exposed to the Lieber-De-Carli diet[43]. More-
over, the disruption of  MyD88-independent signaling, in 
studying TRIF-deficient mice, reported protection from 
alcohol-induced liver disease[44]. Additionally, the lack of  
IRF-3, a transcription factor downstream to TLR4/TRIF, 
resulted in preserving IRF-3-KO mice from alcohol-
induced liver injury, steatosis and inflammation[45]. This 
evidence demonstrates the dispensable role of  MyD88 
adapter in TLR4-mediated liver injury.
Recently, the involvement of  the protein kinase C 
(PKC) activity in the increase of  intestinal permeability 
related to alcohol consumption has been described[46]. 
Specifically, both in vitro and in vivo evidence showed that 
alcohol, in a dose-dependent manner, increases TLR4 ex-
pression, which in turn results in augmented PKC activity. 
The consequent reduction of  occludin phosphorylation 
alters the intercellular junctions, leading to the intestinal 
permeability increment[46].
KCs are the primary cells that respond to LPS 
via TLR4-dependent pro-inflammatory cytokines (as 
TNF-α, IL-1β, IL-8, IL-6) and leading to liver inflamma-
tion. In addition, in animal models of  ethanol exposure, 
hepatocytes can be driven to accumulate lipid and aug-
ment TLR4 levels, altering their TLR4 sensitivity and LPS 
hepatotoxicity[47,48]. Moreover, damaged hepatocytes can 
release high-mobility group box 1 (HMGB1), an endog-
enous ligand that can be recognized by TLR4 and partici-
Ceccarelli S et al . ALD and TLR-induced hepatic damage
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lated KCs exhibited increased levels of  both miRNA-155 
and TNF-α. The same author showed that in alcohol-
fed mice there are augmented serum/plasma miR-155 
levels and an increased quantity of  TNF-α in the liver[59]. 
In the same model, the authors evidenced an increase of  
serum/plasma miR-122 which is known to exert multiple 
functions in hepatocytes as it is important in the regula-
tion of  cholesterol metabolism[59,60]. Furthermore, the 
increase of  both miR-155 and miR-122 was absent in 
TLR4-deficient mice that were preserved from ALD[59]. 
It is also noteworthy that treatment with TLR9 ligands 
(that is CpG) leads to plasma increase of  both miR-155 
and miR-122 and increased levels of  TLR9 and serum 
endotoxin have been reported in alcohol-fed mice[48,59]. 
Actually, to date, diverse TLRs have been extensively 
studied and found to be involved in ALD pathogenesis. 
In the Lieber-DeCarli chronic alcohol feeding model, ex-
pression of  TLR1, 2, 4, 6, 7, 8 and 9 liver mRNA resulted 
from increased enteral administration concomitantly to 
steatosis induction. It has been also demonstrated that 
the alcohol treatment sensitizes hepatic inflammation and 
damage since the triggering of  the TLR1, 2, 4, 6, 7, 8 and 
9 with their specific ligands resulted in TNF-α augmen-
tation. Moreover, TLR expression remained unaffected 
after antibiotic treatment which, however, ameliorated 
the alcoholic fatty liver condition[48]. Recently, Byun et al[61] 
studied the TLR3 involvement in alcohol liver injury both 
in HSCs and KCs in vivo. The authors demonstrated, by 
means of  TLR3-KO and IL-10-KO mice fed a high-fat 
diet with added ethanol, that TLR3 is protective for alco-
holic liver injury and exerts this function by stimulating 
IL-10 production. In more detail, polyinosinic-polycyti-
dylic acid (poly I:C, that is TLR3 ligand) administration 
ameliorated alcoholic liver damage and diminished the 
amount of  TNF-α, IL-6 and monocyte chemoattractant 
protein-1 (MCP-1) in control mice. The preservative ac-
tion of  poly I:C was abrogated in TLR3-KO and IL-10-
KO murine models. Coherently, HSCs and KCs isolated 
from poly I:C-treated animals had higher levels of  IL-10 
than the controls. IL-10 was also over-expressed in vitro 
both in HSCs and KCs in the presence of  poly I:C[61].
The most relevant experimental studies on the in-
volvement of  TLRs in inflammation during ALD are 
summarized in Table 1.
Evidence from human studies
The role of  gut dysbiosis and increased gut permeability 
and endotoxemia into the portal circulation has also been 
extensively explored in patients with ALD[9,62]. Conse-
quently, the critical role exerted by TLR signaling in hu-
Table 1  Experimental evidence of Toll-like receptor involvement in inflammation during alcoholic liver disease
Ref. Experimental model Upstream 
factor
Involved 
TLRs
Effects
Enomoto et al[39], 2000 Ethanol-fed rats LPS TLR4 Kupffer cell activation and consequent 
inflammation
Uesugi et al[40], 2001 TLR4 non-functional mice fed ethanol LPS TLR4 Decreased: 
   Steatosis
   Inflammation
   Focal necrosis
Park et al[51], 2004 HEK293T cells Nox4 TLR4 NF-κB activation
LPS-mediated ROS generation
Gustot et al[48], 2006 Mice fed a modified Lieber-DeCarli diet Increased:
LTA, PGN TLR2    Steatosis
LPS TLR4    Liver weight -aminotransferase levels
flagellin TLR5    Liver mRNA expression of different TLRs.
Addition of multiple bacterial products Increased:
loxoribine TLR7    TNF-α mRNA expression
CpG TLR9    Liver inflammatory infiltrate
Hritz et al[43], 2008 TLR4-(KO) mice feed Lieber-De-Carli diet TLR4 Protection from:
   Alcohol-induced liver damage
   ROS production 
   Inflammation
Bala et al[58], 2011 ALD mouse model LPS TLR4 MiRNA-155 increase and TNF-α levels in isolated 
KCs 
Bala et al[59], 2012 ALD mouse model Plasma increase of:
administered with CpG + LPS CpG TLR9    miR-155, miR-122 and miR-146a 
TLR4-KO Protection from:
LPS TLR4    Alcohol-induced liver disease 
   Increase of both miR-155 and miR-122
Byun  et al[61], 2013 Mice feed high-fat diet plus binge ethanol poly I:C TLR3 Protection from alcoholic liver damage
TLR3 (KO) mice  Preservative action of poly I:C abrogated 
LPS: Lipopolysaccharide; TLR: Toll-like receptor; LTA: Lipoteichoic acid; PGN: Peptidoglycan; TNF: Tumor necrosis factor; NADPH: Nicotinamide adenine 
dinucleotide phosphate; Nox4: NADPH oxidase 4; ROS: Reactive oxygen species; ALD: Alcoholic liver disease; KCs: Kupffer cells; poly I:C: Polyinosinic-
polycytidylic acid.
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man ALD has been investigated. Schäfer et al[63] found 
that circulating CD14 levels were higher in serum from 
patients with severe alcoholic hepatitis than in those from 
healthy controls, suggesting the crucial role of  this TLR4 
co-receptor in ALD. Furthermore, it has been reported 
that the CD14-159C>T polymorphism in patients with 
ALD may significantly correlate with the severity of  dis-
ease and be associated with the risk for alcoholic cirrho-
sis[64,65]. However, no correlation has been found between 
TLR4, TNF-α and IL-1β gene variants and ALD in dif-
ferent populations to date[66,67]. 
Clinical evidence of  the TLR involvement in intra-
hepatic inflammatory response in ALD is still scarce but 
reinforces the experimental data reported above. The role 
of  TLRs on neutrophils in patients with ALD was re-
ported by Stadlbauer et al[68]. These authors demonstrated 
that LPS-induced over-expression of  TLR2, 4 and 9 may 
play a pivotal role in the neutrophil dysfunction observed 
in patients with alcoholic hepatitis and suggested that 
the use of  TLR antagonists was unable to prevent this 
dysfunction, while the use of  an endotoxin scavenger 
might reduce inflammatory response and improve clinical 
outcome[69]. Interestingly, other authors found an impair-
ment of  TLR2 but not TLR4-mediated innate immune 
response in peripheral blood monocytes from patients 
with stable chronic ALD, explaining their susceptibility to 
immunodeficiency and disease worsening[70].
Interestingly, it has been reported that TLR-depen-
dent priming of  B cells might explain the increased 
circulating levels of  immunoglobulins in patients with 
alcoholic liver cirrhosis[71].
As mentioned above, most experimental studies re-
ported that NF-κB transcriptional activity is crucial for 
the TLR signal and Stärkel et al[72] demonstrated that a 
persistent activation of  this transcription factor, an up-
regulation of  TLR3 and TLR7 expression and high pro-
inflammatory cytokine levels were associated with end-
stage ALD and involved in disease progression in humans.
Additional proof  of  the activation of  the TLR-
dependent inflammatory network in ALD was reported 
by the analysis of  circulating levels of  cytokines and 
chemokines. In fact, several authors found high levels of  
pro-inflammatory cytokines, including TNF-α and IL-6, 
in the serum of  actively drinking patients with ALD, 
predicting their outcome and long-term survival[73,74]. In-
terestingly, fibroblast growth factor-inducible 14 (Fn14), 
a member of  the TNF receptor superfamily (member 
12A), was found to be over-expressed in the liver, primar-
ily by hepatic progenitors, in patients with alcoholic hepa-
titis and it correlated with disease severity[75]. In addition, 
it has been reported that several chemokines, including 
IL-8, correlated with a worse prognosis in patients with 
alcoholic hepatitis[76].
Finally, a recent study demonstrated that increased 
serum levels of  chemokine-ligand-1 (CXCL1), an inflam-
matory chemokine mainly expressed by mononuclear 
cells in response to LPS-dependent TLR activation, cou-
pled with a polymorphism in the gene encoding for this 
protein are risk factors for alcoholic cirrhosis[77].
CONCLUSION
ALD remains one of  the major causes of  hepatic-associated 
morbidity and mortality worldwide. Furthermore, the 
current therapeutic options for patients with ALD are 
alcohol abstinence and liver transplantation for end-stage 
liver disease. The liver inflammatory response, which is 
generated early in ALD, is probably triggered by bacteria 
and their products, particularly LPS. Due to increased 
intestinal permeability, they translocate into circulation 
and activate TLR-dependent production and secretion 
of  pro-inflammatory cytokines and chemokines. There 
is a body of  experimental evidence of  the crucial role of  
TLR-mediated inflammatory network in ALD develop-
ment and progression. However, to date, these findings 
have little translational proof  in patients. More studies in 
humans are urgently needed to advance the field and to 
translate experimental/informative findings into novel 
therapies.
Furthermore, as qualitative and quantitative changes 
of  the gut microbiome play a major role in the TLR-
dependent liver inflammatory response and ALD patho-
genesis, further metagenomic, transcriptomic and me-
tabolomic studies may help, not only to explain the “gut-
liver axis’’ in ALD, but also to identify novel potential 
therapeutic targets. In fact, according to previous studies, 
treatment with probiotics inhibits alcohol-induced TLR4 
and TLR5 activation of  TNF-α production, reducing he-
patic inflammation in experimental models, and restores 
neutrophil phagocytic ability in patients with alcoholic 
cirrhosis, probably by changing TLR4 expression and 
IL-10 secretion[78,79].
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